Adsorption column for myasthenia gravis treatment: Medisorba MG-50
- PMID: 12921120
- DOI: 10.1046/j.1526-0968.2003.00008.x
Adsorption column for myasthenia gravis treatment: Medisorba MG-50
Abstract
Adsorption column Medisorba MG-50 (Kuraray Medical Inc.) for the treatment of myasthenia gravis (MG) is introduced. The adsorbent in this column is composed of cellulose beads as carrier material and covalent-bound synthetic peptide as a ligand that has a specific affinity to the pathogenic anti-acetylcholine receptor antibody of MG. The amino acid sequence of the peptide is modified from the segment of alpha 183-200 of the torpedo acetylcholine receptor (AChR) protein, and the segment is the acetylcholine binding site on AChR and the target site of anti-AChR antibody. The adsorbent showed specific adsorption characteristics to the anti-ACHR antibody (blocking antibody) in vitro. Clinically, MG-50 is used in plasma-perfusion therapy, and it is recognized that MG-50 specifically reduces blocking antibody titer and improves MG symptoms. MG-50 is approved in Japan.
Similar articles
-
Specific immunoadsorbent for myasthenia gravis treatment: development of synthetic peptide designed to remove antiacetylcholine receptor antibody.Ther Apher. 1998 Aug;2(3):246-8. doi: 10.1111/j.1744-9987.1998.tb00113.x. Ther Apher. 1998. PMID: 10227779
-
Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis.Transfus Sci. 1996 Sep;17(3):445-53. doi: 10.1016/0955-3886(96)00028-8. Transfus Sci. 1996. PMID: 10163553 Review.
-
Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis.Artif Cells Blood Substit Immobil Biotechnol. 2010 Apr;38(2):99-102. doi: 10.3109/10731191003634778. Artif Cells Blood Substit Immobil Biotechnol. 2010. PMID: 20196680
-
Selective removal of anti-acetylcholine receptor antibodies and IgG in vitro with an immunoadsorbent containing immobilized sulfathiazole.Artif Organs. 1990 Oct;14(5):334-41. doi: 10.1111/j.1525-1594.1990.tb02977.x. Artif Organs. 1990. PMID: 2241600
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
Cited by
-
Extracorporeal immunoglobulin elimination for the treatment of severe myasthenia gravis.J Biomed Biotechnol. 2010;2010:419520. doi: 10.1155/2010/419520. Epub 2010 Mar 15. J Biomed Biotechnol. 2010. PMID: 20300435 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical